Abiopharma

🔍 Miller Deborah Ann (Executive)

Company: Nuvalent, Inc. (NUVL)

Report Date: 2026-04-30

Detailed Transactions and Holdings:

• Acquired 5,500 shares of Class A Common Stock at $6.89 per share (Direct)
  Date: 2026-04-30 | Code: M | equity_swap_involved: false | shares_owned_after: 65,134.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 4,418 shares of Class A Common Stock at $99.13 per share (Direct)
  Date: 2026-04-30 | Code: S | equity_swap_involved: false | shares_owned_after: 60,716.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 1,082 shares of Class A Common Stock at $99.57 per share (Direct)
  Date: 2026-04-30 | Code: S | equity_swap_involved: false | shares_owned_after: 59,634.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 5,500 shares of Stock Option (Right to Buy) at $6.89 per share (Derivative)
  Date: 2026-04-30 | Code: M | Expires: 2031-04-29 | equity_swap_involved: false | shares_owned_after: 78,108.00 | transaction_form_type: 4 | Footnotes: F1, F4

Footnotes:

• F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2024.
• F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.51 to $99.49, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4.
• F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.51 to $99.70, inclusive.
• F4: The shares underlying this option are fully vested.